TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33706186

Group type: EXPERIMENTAL
Intervention: Combination therapy of perindopril, indapamide, and amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UPLC-MS/MS method for quantification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extraction recovery of perindopril, perindoprilat, and indapamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stability of analytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UPLC-MS/MS method
Number of subjects: 0
Study: 35283313

Group type: EXPERIMENTAL
Intervention: BTN162b2
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: mRNA‐1273
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: ChAdOx1 followed by a mRNA vaccine
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: Spike‐ACE2‐receptor‐blocking antibodies
Number of subjects: 6544

Group type: EXPERIMENTAL
Intervention: Age >= 75 years
Number of subjects: 6544
Study: 34812138

Group type: EXPERIMENTAL
Intervention: Unicompartmental knee replacement
Number of subjects: 57938

Group type: COMPARATOR
Intervention: Total knee replacement
Number of subjects: 57938
Study: 32329737

Group type: EXPERIMENTAL
Intervention: Mobile-based messaging intervention (mHealth)
Number of subjects: 59
Study: 36060926

Group type: EXPERIMENTAL
Intervention: rh‐EGF combined with PVI
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 105
Study: 33337904

Group type: EXPERIMENTAL
Intervention: Psychological behaviour management programme (including symbolic modelling, tell‐show‐do, positive reinforcement, distraction) during the second treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Watching cartoon animations during the first treatment and control group during the second treatment
Number of subjects: 48
Study: 35293006

Group type: EXPERIMENTAL
Intervention: D‐VCd (daratumumab, bortezomib, cyclophosphamide, and dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VCd (bortezomib, cyclophosphamide, and dexamethasone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D‐VCd followed by daratumumab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroups with renal and cardiac involvement
Number of subjects: 0
Study: 33285469

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenously every 2 weeks for up to 12 months)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study: 33127967

Group type: EXPERIMENTAL
Intervention: Anesthesia Service Platform (ASP)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 222
Study: 36309127

Group type: EXPERIMENTAL
Intervention: Routine health status assessment via the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Routine KCCQ-12 assessment
Number of subjects: 1248
Study: 34449185

Group type: EXPERIMENTAL
Intervention: Abbreviated therapy (1 month of dual antiplatelet therapy)
Number of subjects: 4434

Group type: COMPARATOR
Intervention: Standard therapy (continuation of dual antiplatelet therapy for at least 2 additional months)
Number of subjects: 4434
Study: 32360692

Group type: EXPERIMENTAL
Intervention: Active cannabis (12.5% THC)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High THC cannabis
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Low THC cannabis
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 91
Study: 34117180

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 104

Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 104
Study: 34384737

Group type: EXPERIMENTAL
Intervention: Multidisciplinary health promotion program for 24 months (11 group sessions: 8 main and 3 support sessions)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care at primary care level
Number of subjects: 92
Study: 34591170

Group type: EXPERIMENTAL
Intervention: Isometric (ISO)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Concentric (CONC)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Eccentric (ECC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: All groups (ISO, CONC, ECC)
Number of subjects: 33
Study: 32189042

Group type: EXPERIMENTAL
Intervention: Treadmill walking with pelvis perturbation force
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treadmill only
Number of subjects: 14
Study: 34847035

Group type: EXPERIMENTAL
Intervention: Active tVNS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 28
Study: 35713517

Group type: EXPERIMENTAL
Intervention: Pyrotinib and trastuzumab with weekly paclitaxel-cisplatin neoadjuvant chemotherapy for four cycles
Number of subjects: 53
Study: 33047784

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 34927293

Group type: EXPERIMENTAL
Intervention: M100 (100 g ML powder per sow per day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: M200 (200 g ML powder per sow per day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: M300 (300 g ML powder per sow per day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: M400 (400 g ML powder per sow per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: C (control group, 0 g ML powder per sow per day)
Number of subjects: 50
Study: 34385704

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 34117835

Group type: EXPERIMENTAL
Intervention: Aqua‐PLYO exercises
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard outpatient care (SoC)
Number of subjects: 16
Study: 34424115

Group type: EXPERIMENTAL
Intervention: Pictorial Asthma Action Plan (PAAP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Written Asthma Action Plan (WAAP)
Number of subjects: 45
Study: 34668795

Group type: EXPERIMENTAL
Intervention: Multimodal nonopioid analgesic protocol (acetaminophen, ketorolac, diazepam, gabapentin, and meloxicam)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard opioid regimen (hydrocodone‐acetaminophen)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multimodal nonopioid analgesic protocol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard opioid regimen
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 32613525

Group type: EXPERIMENTAL
Intervention: Mobile After-Care Support (MACS)
Number of subjects: 10
Study: 32825556

Group type: EXPERIMENTAL
Intervention: 800 mg EGCG
Number of subjects: 14
Study: 34727317

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 953
Study: 35331859

Group type: EXPERIMENTAL
Intervention: IA-HA (2,700 kDa HA, 5 times at 1-week intervals)
Number of subjects: 200

Group type: COMPARATOR
Intervention: NSAID (loxoprofen sodium, 180 mg/day for 5 weeks)
Number of subjects: 200
Study: 33038521

Group type: EXPERIMENTAL
Intervention: Mechanical end-to-end anastomosis
Number of subjects: 33

Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis (subanalysis of low-mid rectum tumors)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 33
Study: 35641198

Group type: EXPERIMENTAL
Intervention: Married
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Divorced/Separated/Widowed
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Living with other family
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Living alone
Number of subjects: 1082
Study: 33407791

Group type: EXPERIMENTAL
Intervention: 8 weeks of exercise and education (Good Life with osteoarthritis in Denmark; GLAD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intra-articular injections of 5 ml isotonic saline every second week for a total of 4 injections
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 8 weeks of exercise and education (GLAD)
Number of subjects: 200
Study: 32871881

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Epidural Analgesia (EA)
Number of subjects: 100
Study: 34467386

Group type: EXPERIMENTAL
Intervention: Live music intervention with standard care
Number of subjects: 33

Group type: COMPARATOR
Intervention: Recorded music intervention with standard care
Number of subjects: 33
Study: 34837890

Group type: EXPERIMENTAL
Intervention: Flexible airway scope (FAS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Retrograde intubation technique (RIT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Comparison of FAS and RIT
Number of subjects: 4
Study: 34473194

Group type: EXPERIMENTAL
Intervention: Ensartinib, 225 mg once daily
Number of subjects: 290

Group type: COMPARATOR
Intervention: Crizotinib, 250 mg twice daily
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Ensartinib
Number of subjects: 290

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 290
Study: 33180670

Group type: EXPERIMENTAL
Intervention: AS04-adjuvanted HPV-16/18 vaccine
Number of subjects: 871
Study: 32741240

Group type: EXPERIMENTAL
Intervention: 6-month social ballroom dancing intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: 6-month active control intervention (treadmill walking)
Number of subjects: 32
Study: 34764183

Group type: EXPERIMENTAL
Intervention: 6-week twice-weekly regimen of rifapentine plus isoniazid
Number of subjects: 2449

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 2449
Study: 33516273

Group type: EXPERIMENTAL
Intervention: SNPs (rs11682128, rs601945, rs3935067, rs679515)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differential expression analysis of BIN1 gene
Number of subjects: 0
Study: 32827645

Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic (GAL) procedures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional laparoscopic (COL) operations
Number of subjects: 100
Study: 35580967

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 216

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 216
Study: 33075163

Group type: EXPERIMENTAL
Intervention: Mailed hard copy binder
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Interactive website (https://www.task3web.com/)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: eBook
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: USB drive
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Telephone calls with nurse
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: FaceTime on iOS device
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Online videoconferencing
Number of subjects: 22
Study: 32070472

Group type: EXPERIMENTAL
Intervention: Electronic Asthma Education Program (eAEP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional face-to-face Asthma Education Program (pAEP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Electronic Asthma Education Program (eAEP) after pAEP
Number of subjects: 82
Study: 35835613

Group type: EXPERIMENTAL
Intervention: Cancer-related fatigue (CRF) trajectory - Always present
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cancer-related fatigue (CRF) trajectory - Subsided
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cancer-related fatigue (CRF) trajectory - Developed
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cancer-related fatigue (CRF) trajectory - Never present
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Overall impact of CRF on HRQOL
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Fatigue management
Number of subjects: 202
Study: 34672928

Group type: EXPERIMENTAL
Intervention: 1-day acceptance and commitment therapy (ACT) workshop
Number of subjects: 72

Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 72
Study: 36017745

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 1134
Study: 36916653

Group type: COMPARATOR
Intervention: Topical corticosteroids (TCS)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus (TAC)
Number of subjects: 152
Study: 33542412

Group type: COMPARATOR
Intervention: Hylan G-F 20 (HG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Platelet concentrate (PCG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide (THG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stanozolol (SG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 100
Study: 32482355

Group type: EXPERIMENTAL
Intervention: 0.2 μg.kg−1 remifentanil combined with propofol
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.3 μg.kg−1 remifentanil combined with propofol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Propofol alone (Control Group)
Number of subjects: 105
Study: 34968635

Group type: EXPERIMENTAL
Intervention: Tobacco-Free Duo (T-Duo) multi-component intervention
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Standardized educational component (control)
Number of subjects: 1776
Study: 34886324

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove and fuel intervention (n = 1590)
Number of subjects: 3195

Group type: COMPARATOR
Intervention: Control group (n = 1605)
Number of subjects: 3195
Study: 32159606

Group type: EXPERIMENTAL
Intervention: Dorsal to Plantar screw orientation (DP Group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plantar to Dorsal screw orientation (PD Group)
Number of subjects: 16
Study: 35224781

Group type: EXPERIMENTAL
Intervention: 10 commercially available sunscreens
Number of subjects: 20
Study: 32861273

Group type: EXPERIMENTAL
Intervention: Veliparib plus carboplatin and paclitaxel
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo plus carboplatin and paclitaxel
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study: 36341961

Group type: EXPERIMENTAL
Intervention: Multi-component interventions tailored to FCG needs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized terminology and pathway for tailoring intervention components
Number of subjects: 0
Study: 34770104

Group type: EXPERIMENTAL
Intervention: 30 min exercise (high-intensity intermittent running)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 60 min exercise (high-intensity intermittent running)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 38
Study: 32155382

Group type: EXPERIMENTAL
Intervention: Educational intervention using WhatsApp messaging (55 audio, image or text messages) plus usual care (multi‐professional educational appointments)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 403
Study: 34156650

Group type: EXPERIMENTAL
Intervention: Exergaming intervention
Number of subjects: 35
Study: 34005897

Group type: EXPERIMENTAL
Intervention: α model (targeted percolation with incomplete knowledge)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β model (mirror image process targeting the lowest degree node)
Number of subjects: 0
Study: 34298389

Group type: EXPERIMENTAL
Intervention: Eyes open and focused during MRI acquisition
Number of subjects: 77

Group type: COMPARATOR
Intervention: Eyes closed during MRI acquisition
Number of subjects: 77
Study: 32067341

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) program for 8 weeks incorporating Optifast shakes
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care (generic healthy eating information)
Number of subjects: 46
Study: 33217220

Group type: EXPERIMENTAL
Intervention: Maxillomandibular fixation (MMF) with orthodontic bracket‐elastic, immobilization for 2 weeks and guiding elastics for 1 week
Number of subjects: 17
Study: 32054559

Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36001000

Group type: EXPERIMENTAL
Intervention: Pexidartinib
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 34212195

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) 3 or 6 million units/m2
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 35
Study: 32610864

Group type: EXPERIMENTAL
Intervention: Daily oral iron supplementation (60mg of elemental iron, ferrous sulfate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alternate day oral iron supplementation (60mg of elemental iron, ferrous sulfate)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Daily oral iron supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alternate day oral iron supplementation
Number of subjects: 40
Study: 36120967

Group type: EXPERIMENTAL
Intervention: Conjoint Behavioral Consultation (CBC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: School-as-usual
Number of subjects: 30
Study: 34105575

Group type: EXPERIMENTAL
Intervention: 3 whole Gala apples (∼200 g)
Number of subjects: 26
Study: 35142833

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive Behavior Therapy (CCBT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 175
Study: 33361317

Group type: EXPERIMENTAL
Intervention: Navy bean intervention (35 g bean powder/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (0 g/day)
Number of subjects: 20
Study: 34383381

Group type: EXPERIMENTAL
Intervention: MMC + cytosine arabinoside (Ara‐C) therapy (30 mg/30 mL + 200 mg/10 mL) for 6 weeks
Number of subjects: 165

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) therapy (30 mg/40 mL) for 6 weeks
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: MMC + Ara‐C therapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: MMC therapy
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: MMC and Ara‐C therapy
Number of subjects: 165
Study: 33610093

Group type: EXPERIMENTAL
Intervention: Patient Navigation + Contingency Management (PN + CM)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Patient Navigation alone (PN)
Number of subjects: 801
Study: 32114796

Group type: EXPERIMENTAL
Intervention: Single 10-second ECG
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Twice-daily 30-second ECGs during 14 days
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Single 24-hour continuous monitoring
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Single 48-hour continuous monitoring
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Single 72-hour continuous monitoring
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Single 7-day continuous monitoring
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Single 30-day continuous monitoring
Number of subjects: 590
Study: 36004636

Group type: EXPERIMENTAL
Intervention: CleanViewAL®
Number of subjects: 173

Group type: COMPARATOR
Intervention: Plenvu®
Number of subjects: 173
Study: 33560531

Group type: EXPERIMENTAL
Intervention: XP‐endo Shaper
Number of subjects: 60

Group type: COMPARATOR
Intervention: iRaCe rotary files
Number of subjects: 60
Study: 32807179

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Moderate intensity continuous training (MICT)
Number of subjects: 81
Study: 35412010

Group type: EXPERIMENTAL
Intervention: Intervention group (weight loss intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 0
Study: 34677629

Group type: EXPERIMENTAL
Intervention: Non-tourniquet (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tourniquet (Group B)
Number of subjects: 90
Study: 34116911

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 46
Study: 33113452

Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 152
Study: 35270619

Group type: EXPERIMENTAL
Intervention: Small-Sided Games (SSGs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 32
Study: 34973108

Group type: EXPERIMENTAL
Intervention: Avelumab + BSC
Number of subjects: 73

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 73
Study: 32588803

Group type: EXPERIMENTAL
Intervention: Vi-polysaccharide (ViPS) typhoid vaccine
Number of subjects: 14797
Study: 35143747

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT) plus physiotherapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Physiotherapy alone (Control)
Number of subjects: 26
Study: 32314015

Group type: EXPERIMENTAL
Intervention: 3 mg vaginal dinoprostone
Number of subjects: 200
Study: 35771891

Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside (20 mg.kg‐1 up to 1000 mg over 30 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual preoperative care (control)
Number of subjects: 40
Study: 32529940

Group type: EXPERIMENTAL
Intervention: Transparent film dressing
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 110
Study: 34593344

Group type: EXPERIMENTAL
Intervention: Intervention involving the use of the PADR-EC ADR score communicated to clinicians and discussed with participants, followed by medication management advice to general practitioners and community pharmacists.
Number of subjects: 0
Study: 33491087

Group type: EXPERIMENTAL
Intervention: Intensive therapy (HbA1c < 6.2%, blood pressure < 120/75 mm Hg, LDL-cholesterol < 80 mg/dL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (HbA1c < 6.9%, blood pressure < 130/80 mm Hg, LDL-cholesterol < 120 mg/dL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: History of smoking at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FRAX score [%/10 years] at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of pioglitazone at 1 year after randomization
Number of subjects: 0
Study: 32004772

Group type: COMPARATOR
Intervention: Fluvastatin (multiple oral doses: 20, 40 or 80 mg/day for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atorvastatin (single oral dose: 20, 40 or 80 mg)
Number of subjects: 30